BioNexus Gene LabBGLC
Market Cap: 8.64M
About: BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.
Employees: 30
Fund manager confidence
Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)
100% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 0
26% more capital invested
Capital invested by funds: $55.9K [Q4 2023] → $70.7K (+$14.8K) [Q1 2024]
0.02% less ownership
Funds ownership: 0.59% [Q4 2023] → 0.57% (-0.02%) [Q1 2024]
20% less funds holding
Funds holding: 5 [Q4 2023] → 4 (-1) [Q1 2024]
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Research analyst outlook
We haven’t received any recent analyst ratings for BGLC.